Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Depreciation & Amortization (CF) (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 17.62% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 22.09% increase, with the full-year FY2025 number at $6.4 million, up 22.09% from a year prior.
  • Depreciation & Amortization (CF) was $1.7 million for Q4 2025 at PROCEPT BioRobotics, up from $1.6 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q4 2025 to a low of $642000.0 in Q2 2023.
  • A 5-year average of $1.1 million and a median of $984500.0 in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): fell 17.16% in 2022, then soared 98.79% in 2023.
  • PROCEPT BioRobotics' Depreciation & Amortization (CF) stood at $763000.0 in 2021, then dropped by 13.11% to $663000.0 in 2022, then skyrocketed by 98.79% to $1.3 million in 2023, then increased by 10.24% to $1.5 million in 2024, then rose by 17.62% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Depreciation & Amortization (CF) are $1.7 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025).